Administration of cardiac mesenchymal cells modulates innate immunity in the acute phase of myocardial infarction in mice
Abstract Although cardiac mesenchymal cell (CMC) therapy mitigates post-infarct cardiac dysfunction, the underlying mechanisms remain unidentified. It is acknowledged that donor cells are neither appreciably retained nor meaningfully contribute to tissue regeneration—suggesting a paracrine-mediated...
Guardado en:
Autores principales: | Yi Kang, Marjan Nasr, Yiru Guo, Shizuka Uchida, Tyler Weirick, Hong Li, Jae Kim, Joseph B. Moore, Senthilkumar Muthusamy, Roberto Bolli, Marcin Wysoczynski |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e60037ebf1604f059252e71ae039ca99 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Innate Lymphoid Cells and Myocardial Infarction
por: Wenling Yang, et al.
Publicado: (2021) -
Cardiac Tissue Engineering for the Treatment of Myocardial Infarction
por: Dongmin Yu, et al.
Publicado: (2021) -
Optimization of Timing and Times for Administration of Atorvastatin‐Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction
por: Jun Xu, et al.
Publicado: (2019) -
Eosinophils improve cardiac function after myocardial infarction
por: Jing Liu, et al.
Publicado: (2020) -
Haematopoietic and cardiac GPR55 synchronize post-myocardial infarction remodelling
por: Sarah-Lena Puhl, et al.
Publicado: (2021)